我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

辛伐他汀和氟伐他汀对冠心病患者C反应蛋白的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2002年第5期
页码:
396-398
栏目:
临床研究
出版日期:
2002-09-01

文章信息/Info

Title:
Effects of Simvastatin and Fluvastatin on the plasma levels of C-reactive protein in patient with coronary heart disease
作者:
赵季红;  张利华;  柳 荫;  薛玉生;  刘 军
第四军医大学唐都医院心内科,陕西西安710038
Author(s):
ZHAO Ji-hong; ZHNAG Li-hua; LIU Yin; XUE Yu-sheng; LIU Jun
Department of Cardiology, Tangdu Hospital of Fourth Military Medical University, Xi' an Shaanxi 710038,China
关键词:
冠状动脉疾病; 辛伐他汀; 氟伐他汀; 炎症; C反应蛋白质
Keywords:
coronary disease;  Simvastatin;  Fluvastatin;  inflammation;  C-reactive protein.
分类号:
R514.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨辛伐他汀和氟伐他汀对冠心病(CHD)患者血浆C反应蛋白(CRP)水平的影响。方法 将156例CHD患者随机分为3组,分别给予口服安慰剂(A组)、辛伐他汀(B组)、氟伐他汀(C组),采用散射光比浊法测定3组患者用药前及用药后4,6,8周血浆的CRP浓度、总胆固醇(TC)浓度。结果 ①B组及C组患者用药后4,6,8周,血浆CRP水平均明显低于A组(P<0.05,P<0.01,P<0.01)。②B组及C组患者血浆CRP水平在用药后4,6,8周呈逐渐下降趋势,与用药前相比,均有显著性差异(P<0.05,P<0.01,P<0.01)。③B组及C组患者血浆TC水平在用药后4,6,8周呈逐渐下降趋势,与用药前相比,均有显著性差异(P<0.05,P<0.05,P<0.01)。④B组及C组患者的血浆CRP水平的降低与血浆TC水平的降低不相关(P>0.05)。结论 辛伐他汀和氟伐他汀降低CHD患者血脂的同时,具有抗炎症反应作用。
Abstract:
AIM To explore the effects of Simvastatin and Fluvastatin on the plasma levels of C reactive protein (CRP) in patient with coronary heart disease(CHD).METHODS 156 CHD patients were randomly divided into three groups:Group A treated with placebo,Group B with simvastatin and Group C with fluvastatin,and their plasma CRP and total cholesterol(TC) levels were measured by nephelometry before and 4,6 and 8 weeks after the treatment.RESULTS ①4,6 and 8 weeks after the treatment,the plasma CRP levels of Groups B and C were significantly lower than those of Group A(P<0.05,P<0.01 and P<0.01 respectively).②Both B group and C goup were treated after 4 weeks,6 weeks,8 weeks,their plasma levels of CRP were significantly lower than that before treated(respectivelyP<0.05,P<0.01,P<0.01).③In Groups B and C, the plasma TC levels were markedly lower 4,6 and 8 weeks after the treatment than before the treatment (P<0.05,P<0.05 and P<0.01 respectively).④There was no correlation between the decrease of CRP levels and that of TC levels in Groups B and C(P>0.05).CONCLUSION Lipid lowering therapy with simvastatin and fluvastatin have beneficial effects on antiinflammation.

参考文献/References

[1] Roivainen M, Kajander MV, Palosuo T,et al.Infections, inflammation, and the risk of coronary heart disease[J].Circulation, 2000,101:252-257.

[2] 方 圻,王钟林,宁田海,等,血脂异常防治建议[J].中华心血管病杂志, 1997,25(3):169-175.

[3] 惠汝太.炎症反应与动脉粥样硬化及急性冠状动脉综合征[J].中国循环杂志, 2000,15(5):259-260.

[4] Austin MA. Epidemiology of hypertriglyceridemia and cardiovascular disease[J].Am J Cardiol, 1999,83:13F-16F.

[5] Aikama M, Rabkin E, Okada Y,et al. Lipid Lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma[J].Circulation, 1998,97:2433-2444.

[6] Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction[J].Circulation, 1998,97:2007-2011.

[7] Jianhui Zhu, Quyyumi AA, Norman JE,et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels[J].Am J Cardiol, 2000,85:140-146.

[8] Wolf MG, Zasmeta G, Hornykewycz S,et al. Plasma levels of C-reactive protein after coronary stent implantation[J].Eur Heart J, 2000,21:1152-1158.

[9] The ENCORE trials. Endothelial dysfunction as a therapeutic target[J].Eur Heart J Supplements, 2000,1(Suppl D):D20-D25.

[10] Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease [J].Lancet, 1999,353: 118-119.

[11] Ridker PM, Rifai N, Pfeffer MA,et al. Long term effects of pravastatin on plasma concentration of C-reactive protein[J].Circulation, 1999,100:230-235.

备注/Memo

备注/Memo:
收稿日期：2001-03-09.
更新日期/Last Update: 2002-09-01